Servier is a French multinational pharmaceutical company, founded in 1954 by Dr. Jacques Servier. It operates in over 150 countries and focuses on research, development, and production of medicines, particularly in therapeutic areas such as cardiovascular diseases, oncology, diabetes, immuno-inflammatory diseases, and neuropsychiatric disorders.
Here are some key aspects of Servier:
Therapeutic Focus:
Cardiovascular Diseases: Servier has a long history of developing drugs for conditions like hypertension, heart failure, and stroke prevention. Oncology: In recent years, Servier has increased its focus on cancer treatments, with an expanding oncology portfolio that includes drugs for various types of cancers, such as colon and blood cancers. Diabetes: Servier also develops medications for type 2 diabetes, including products to manage blood sugar levels and associated cardiovascular risks. Innovation and R&D: Servier is highly research-oriented, reinvesting a significant portion of its revenue into research and development. The company is particularly known for its commitment to innovative therapies and novel drugs across various medical conditions, with a strong focus on precision medicine and personalized treatment.
Acquisitions and Collaborations: Servier has made several strategic partnerships and acquisitions to expand its portfolio, particularly in oncology and other therapeutic areas. It has collaborated with academic institutions, research organizations, and other pharmaceutical companies to accelerate the development of new treatments.
Global Presence: Servier is one of the largest independent pharmaceutical companies in Europe, and despite its global operations, it remains privately held. This independence allows the company to reinvest profits into research and maintain a long-term vision focused on therapeutic advancements.
Overall, Servier is recognized for its contributions to cardiovascular and metabolic diseases, with a growing reputation in oncology, making it a key player in the global pharmaceutical industry.